The American Thyroid Association and American Association of Clinical Endocrinologists Hyperthyroidism and Other Causes of Thyrotoxicosis Guidelines: Viewpoints from Japan and Korea
Restricted accessEditorialFirst published online June, 2011
The American Thyroid Association and American Association of Clinical Endocrinologists Hyperthyroidism and Other Causes of Thyrotoxicosis Guidelines: Viewpoints from Japan and Korea
ATA/AACE Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis. BahnRS, BurchHB, CooperDS, GarberJR, GreenleeMC, KleinI, LaurbergP, McDougallIR, MontoriVM, RivkeesSA, RossDS, SosaJA, StanMN. 2011. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid, 21:593–646.
2.
WartofskyL, GlinoerD, SolomonB, NagatakiS, LagasseR, NagayamaY, IzumiM. 1991. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan and the United States. Thyroid, 1:129–135.
3.
NakamuraH. 2006. Guideline for treatment of Graves' disease with antithyroid drugs in Japan. Nippon Rinsho, 64:2243–2249. In Japanese.
4.
TakataK, KubotaS, FukataS, KudoT, NishiharaE, ItoM, AminoN, MiyauchiA. 2009. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid, 19:559–563.
5.
NakamuraH, NohJY, ItohK, FukataS, MiyauchiA, HamadaN. 2007. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab, 92:2157–2162.
6.
OritoY, OkuH, KubotaS, AminoN, ShimogakiK, HataM, MankiK, TanakaY, SuginoS, UetaM, KawakitaK, NunotaniT, TatsumiN, IchiharaK, MiyauchiA, MiyakeM. 2009. Thyroid function in early pregnancy in Japanese healthy women: relation to urinary iodine excretion, emesis, and fetal and child development. J Clin Endocrinol Metab, 94:1683–1688.
7.
Yoshimura NohJ, MiyazakiN, ItoK, TakedaK, HiramatsuS, MoritaS, MiyauchiA, MurakamiT, InomataK, NoguchiS, SatohT, AminoN. 2008. Evaluation of a new rapid and fully automated electrochemiluminescence immunoassay for thyrotropin receptor autoantibodies. Thyroid, 18:1157–1164.
8.
OtaH, AminoN, MoritaS, KobayashiK, KubotaS, FukataS, KamiyamaN, MiyauchiA. 2007. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf), 67:41–45.
9.
NishiharaE, ChenCR, HigashiyamaT, Mizutori-SasaiY, ItoM, KubotaS, AminoN, MiyauchiA, RapoportB. 2010. Subclinical nonautoimmune hyperthyroidism in a family segregates with a thyrotropin receptor mutation with weakly increased constitutive activity. Thyroid, 20:1307–1314.
10.
AminoN, HidakaY, TakanoT, TatsumiKI, IzumiY, NakataY. 2003. Possible induction of Graves' disease and painless thyroiditis by gonadotropin-releasing hormone analogues. Thyroid, 13:815–818.
11.
WarfofskyL. 1973. Low remission rate after therapy for Graves' disease. Possible relation of dietary iodine with antithyroid therapy results. JAMA, 26:1083–1088.
12.
RotiE, GardiniE, MinelliR, BianconiL, SalviM, GavaruzziG, BravermanLE. 1993. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism. J Clin Endocrinol Metab, 76:928–932.
13.
DaiWX, LianXI, LiSH, LiXW. 2006. Effect of universal salt iodination on antithyroid drugs. Chin Med J, 119:1108–1112.
14.
AbrahamP, AvenellA, McGreochSC, ClarkLF, BevaJS. 2010. Antithyroid drug regimen for treating Graves' hyperthyroidism (Review)Cochrane Database Syst Rev, 2010:CD003420.
15.
HashizumeK, IchikawaK, SakuraiA, SuzukiS, TakedaT, KobayashiM, MiyamotoT, AraiM, NagasawaT. 1991. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med, 324:947–953.
16.
ChoBY, ShongMH, YiKH, LeeHK, KohCS, MinHK. 1992. Evaluation of serum basal thyrotropin levels and thyrotropin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease. Clin Endocrinol, 36:585–590.
17.
KonishiT, OkamotoY, UedaM, FukudaY, HarusatoI, TsukamotoY, HamadaN. 2011. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease; a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J, 58:95–100.
18.
MazzaE, CarliniM, FlecchiaA, BlattoA, ZuccariniO, GambaS, BeninatiS, MessinaM. 2008. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest, 31:866–872.
19.
Feldt-RasmussenU, SchleusenerH, CarayonP. 1994. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab, 78:98–102.
20.
LaubergP, Buchholtz HansenPE, IversenE, Eskjaer JensenS, WeekeJ. 1986. Goiter size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh), 111:39–43.
